Cell-based interventions for neurologic conditions: ethical challenges for early human trials.

@article{Pullicino2009CellbasedIF,
  title={Cell-based interventions for neurologic conditions: ethical challenges for early human trials.},
  author={Patrick M. Pullicino and William M. J. Burke},
  journal={Neurology},
  year={2009},
  volume={72 19},
  pages={1709; author reply 1709}
}
1. Lindsey JW, Crawford MP, Hatfield LM. Soluble Nogo-A in CSF is not a useful biomarker for multiple sclerosis. Neurology 2008;71:35–37. 2. Jurewicz A, Matysiak M, Raine CS, Selmaj K. Soluble Nogo-A, an inhibitor of axonal regeneration, as a biomarker for multiple sclerosis. Neurology 2007;68:283–287. 3. Reindl M, Khantane S, Ehling R, et al. Serum and cerebrospinal fluid antibodies to Nogo-A in patients with multiple sclerosis and acute neurological disorders. J Neuroimmunol 2003;145:139–147.